NCT03236428View on ClinicalTrials.gov

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

October 4, 2026

Study Completion Date

October 4, 2026

Conditions
Monoclonal GammopathySmoldering Multiple Myeloma
Interventions
DRUG

Daratumumab

Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule

Trial Locations (6)

48201

Karmanos Cancer Insitute, Detroit

80218

Colorado Blood Cancer Institute, Denver

93940

Pacific Cancer Care, Monterey

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Blood Cancer Research Partnership

OTHER

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT03236428 - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter